Biomarkers of Exposure and Effect in the Lungs of Smokers, Nonsmokers, and Electronic Cigarette Users

Min-Ae Song, Jo L. Freudenheim, Theodore M. Brasky, Ewy A. Mathe, Joseph P. McElroy, Quentin A. Nickerson, Sarah A. Reisinger, Dominic J. Smiraglia, Daniel Y. Weng, Kevin L. Ying, Mark D. Wewers, and Peter G. Shields

ABSTRACT

Background: Nicotine-containing electronic cigarette (e-cig) use has become widespread. However, understanding the biological impact of e-cigs compared with smoking on the lung is needed. There are major gaps in knowledge for chronic effects and for an etiology to recent acute lung toxicity leading to death among vapers.

Methods: We conducted bronchoscopies in a cross-sectional study of 73 subjects (42 never-smokers, 15 e-cig users, and 16 smokers). Using bronchoalveolar lavage and brushings, we examined lung inflammation by cell counts, cytokines, genome-wide gene expression, and DNA methylation.

Results: There were statistically significant differences among never-smokers, e-cig users, and smokers for inflammatory cell counts and cytokines (FDR \( q < 0.1 \)). The e-cig users had values intermediate between smokers and never-smokers, with levels for most of the biomarkers more similar to never-smokers. For differential gene expression and DNA methylation, e-cig users also more like never-smokers; many of these genes corresponded to smoking-related pathways, including those for xenobiotic metabolism, aryl hydrocarbon receptor signaling, and oxidative stress. Differentially methylated genes were correlated with changes in gene expression, providing evidence for biological effects of the methylation associations.

Conclusions: These data indicate that e-cigs are associated with less toxicity than cigarettes for smoking-related pathways. What is unknown may be unique effects for e-cigs not measured herein, and a comparison of smokers completely switching to e-cigs compared with former smokers. Clinical trials for smokers switching to e-cigs who undergo serial bronchoscopy and larger cross-sectional studies of former smokers with and without e-cig use, and for e-cigs who relapse back to smoking, are needed.

Impact: These data can be used for product regulation and for informing tobacco users considering or using e-cigs. What is unknown may be unique effects for e-cigs not measured herein, and clinical trials with serial bronchoscopy underway can demonstrate a direct relationship for changes in lung biomarkers for smokers. Although it is suspected that adverse chronic effects of e-cigs are less than continued smoking, there is little direct data for effects in target organs, particularly the lung. Importantly, as of December 10, 2019, 2,409 cases of acute lung injury, including 52 deaths from all 50 states, the District of Columbia, and two U.S. territories (Puerto Rico and U.S. Virgin Islands), were identified to be associated with e-cigarette product use or vaping across the nation (5–8). Many of these cases appear to be related to vaping cannabinoid oils (e.g., a different formulation than what is in nicotine e-cigs), but there are some reported cases in nicotine e-cig users. Thus, studies for the effects of nicotine-containing e-cigs are needed, particularly in the target organ such as the human lung.

E-cigs delivering nicotine by heating liquids contain flavors, propylene glycol (PG) and vegetable glycerin (VG). Although PG and VG are “generally regarded as safe” by the FDA when used in foods and cosmetic products (https://www.atdsr.cdc.gov/toxprofiles/p189-c1.pdf), their safety when inhaled as heated e-aerosols is unknown. Concerns revolve around e-aerosol constituents (e.g., volatile organic compounds) and in vivo and in vitro effects on inflammation, innate immune function, oxidative stress, cytotoxicity, and genotoxicity (9, 10). In humans, urinary and blood carcinogen biomarkers are substantially lower among e-cig users compared with smokers (9, 11–13), whereas sputum and exhaled air studies show increased inflammation with e-cig use (9, 14, 15). Changes in lung proteomics, proteases, and gene expression have been shown to be associated with e-cig use in subjects undergoing bronchoscopy (16–18). Our research group found that there were changes in lung inflammomasomes with e-cig use using the same study set as reported herein (19). The FDA has deemed regulatory authority

Note: Supplementary data for this article are available at Cancer Epidemiology, Biomarkers & Prevention Online (http://cebp.aacrjournals.org/).

Corresponding Author: Peter G. Shields, The Ohio State University, 460 W. 10th Avenue, 9th Floor, Suite D920, Columbus, OH 43210-1240. Phone: 614-688-6563; Fax: 614-293-3132; E-mail: Peter.Shields@osumc.edu

doi: 10.1158/1055-9965.EPI-19-1245
©2019 American Association for Cancer Research.
over e-cigs, but it currently does not regulate the marketing of e-cigs. To address the need for data regarding effects of e-cigs on the lung and to inform policy determination, we conducted a cross-sectional bronchoscopy study of never-smokers, exclusive e-cig users, and cigarette smokers to assess group differences, examining inflammatory infiltrates, cytokines, genome-wide DNA methylation, and gene expression in the lung. Given the recent epidemic of acute lung injury and deaths of some cases may be related to solely nicotine-containing e-cigs, this study is of great importance.

Materials and Methods

Participants and study design

Healthy adults, age 21 to 30, willing to undergo bronchoscopy, were recruited from local print and television media (details regarding recruitment including inclusion and exclusion criteria are in the Supplementary Methods). Although subjects were excluded who reported regular marijuana use, urinary carboxy-tetrahydrocannabinol (THC) was assessed for later correction. The bronchoscopy included a bronchial brushing sample (BAL) and bronchial epithelial brushing of grossly normal airway epithelium from the main bronchus. This study was approved by the Ohio State University Institutional Review Board (the IRB approval number: 2015C0088; ClinicalTrials.gov: NCT02596685).

Carboxy-THC

Gas chromatography-mass spectrometry was used to assess the presence of carboxy-THC by Mayo Clinic Laboratories (https://www.mayocliniclabs.com/test-catalog/Performance/8898) indicating recent marijuana use.

BAL cell counts and inflammatory cytokines

Automated cell counts from BAL were obtained by the Countess Automated Cell Counter (Invitrogen). Differential counting was performed on Diff-Quik stained cytospins under light microscopy by a clinical histopathologist blinded to participant smoking status. BAL fluid samples were analyzed from supernatant using a V-PLEX Plus Proinflamm Combo 10 panel that includes tobacco-smoking-associated proinflammatory cytokines (IFNγ, IL1β, IL2, IL4, IL6, IL10, IL12p70, IL13, and TNFα; Meso Scale Discovery).

Whole transcriptome array and genome-wide DNA methylation

Total RNA was extracted from the bronchial brushing using an Allprep DNA/RNA kit (Qiagen) and assayed for gene expression using the GeneChip Human Transcriptome Array 2.0 (Affymetrix Inc.). The raw data (CEL files) were imported into the Partek Genomics Suite 6.6 for log2 transformation and quantile normalization. ANOVA was used to remove potential batch effects. A subset of subjects (32 of 72) were analyzed for genome-wide DNA methylation and gene expression, unsupervised analysis including unsupervised hierarchical clustering (24) and principal component analysis (PCA; ref. 25) were performed. For heatmaps, the Euclidean distance among groups was calculated by the average linkage.

Ingenuity pathway analysis

Differentially methylated or expressed genes were classified by ingenuity pathway analysis (IPA; Ingenuity Systems, www.ingenuity.com). The IPA comparison analysis tool was used to compare two datasets, taking into account the canonical pathway rank according to the calculated P value across all observations and reporting it hierarchically. The score [score = −log10(P value)] is a measure of the probability of finding identified genes in a set of a list of biological functions stored in the IPA knowledge base by chance alone.

Results

Characteristics of study subjects

There were 73 participants: 16 current smokers, 15 e-cig users, and 42 never-smokers (Table 1). The average age was 26 (range, 21–30), and 47% were women. Smokers averaged 16 cigs/day (range, 10–20) and had smoked for a mean of 6.6 years (range, 0.6–13). All but one e-cig user (a cartridge-type e-cig) vaped flavored tank system e-cigs. All but three e-cig users were former smokers; the others were never-smokers. E-cig users had a mean duration of e-cig use of 2.6 years (range, 0.5–4), and their mean years of smoking, when smoking, was 7.5 years (range, 1–15). Mean daily use of e-cigs was 163 puffs per day (range, 20–600), comparable with other studies (26, 27). Demography, smoking/e-cig history, and THC testing results of individual e-cig subjects are provided in Supplementary Table S1.

Altered BAL inflammatory cells and cytokines in BAL fluids

There were statistically significant overall differences among the three groups for inflammatory infiltrates (FDR q < 0.1; Table 2). Compared with never-smokers, smokers had higher total cell counts (raw P = 0.004), total cell concentrations (raw P = 0.0003), macrophage cell counts (raw P < 0.0001), and neutrophil cell counts (raw P = 0.01). Lymphocyte cell counts were lower (raw P = 0.02). E-cig users’ counts were intermediate between those of smokers and never-smokers except for percentage of macrophages and neutrophil...
Table 1. Characteristics of study participants.

<table>
<thead>
<tr>
<th>Cross-sectional study (n = 73)</th>
<th>Never-smokers (n = 42)</th>
<th>E-cig users (n = 15)</th>
<th>Smokers (n = 16)</th>
<th>P value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years, average (range)</td>
<td>25 (21–30)</td>
<td>27 (21–30)</td>
<td>26 (21–30)</td>
<td>0.19</td>
</tr>
<tr>
<td>Gender</td>
<td>25 (60%)</td>
<td>5 (33%)</td>
<td>4 (25%)</td>
<td>0.03</td>
</tr>
<tr>
<td>Females, N (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Race</td>
<td>31 (74%)</td>
<td>12 (80%)</td>
<td>14 (88%)</td>
<td>0.86</td>
</tr>
<tr>
<td>White, N (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Black or African American, N (%)</td>
<td>3 (7%)</td>
<td>1 (7%)</td>
<td>1 (6%)</td>
<td></td>
</tr>
<tr>
<td>Asian, N (%)</td>
<td>7 (17%)</td>
<td>1 (7%)</td>
<td>1 (6%)</td>
<td></td>
</tr>
<tr>
<td>More than one race, N (%)</td>
<td>1 (2%)</td>
<td>1 (7%)</td>
<td>0 (0%)</td>
<td></td>
</tr>
<tr>
<td>Smoking</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Former, N (%)</td>
<td>0 (0%)</td>
<td>12 (80%)</td>
<td>0 (0%)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Current, N (%)</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td>16 (100%)</td>
<td></td>
</tr>
<tr>
<td>Never, N (%)</td>
<td></td>
<td></td>
<td>3 (20%)</td>
<td></td>
</tr>
<tr>
<td>Years of smoking, average (range)</td>
<td></td>
<td>7.5 (1–15)b</td>
<td>6.6 (0.6–13)</td>
<td>0.69</td>
</tr>
<tr>
<td>Cigarettes per day, average (range)</td>
<td></td>
<td>12.6 (0.7–20)b</td>
<td>16 (10–20)</td>
<td>0.24</td>
</tr>
<tr>
<td>Years since last cigarettes, average (range)</td>
<td></td>
<td>2.1 (0.4–4.1)c</td>
<td></td>
<td></td>
</tr>
<tr>
<td>E-cig use</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Years of e-cig use, average (range)</td>
<td></td>
<td>2.6 (0.5–4)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Puffs per day, average (range)</td>
<td></td>
<td>163.3 (20–600)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>E-liquid (mL) per day, average (range)</td>
<td></td>
<td>8.3 (2–20)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nicotine (mg/mL), average (range)</td>
<td></td>
<td>10.7 (1.5–36)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Kruskal–Wallis (among three groups) or Mann–Whitney test (between two groups) for continuous variables; Fisher exact test for categorical variables.

Counts which were the same for never-smokers and e-cig users. Median cell concentration for the e-cig users was lower than for smokers (306 × 10⁶/L, 434 × 10⁶/L, respectively, raw P = 0.05) and higher than the never-smokers (238 × 10⁶/L, raw P = 0.22). Macrophage counts for e-cig users were lower than for smokers (raw P = 0.02) and higher than for never-smokers (raw P = 0.13).

For all but two of the 10 inflammatory cytokines measured, the e-cig users’ values were intermediate between those of the smokers and never-smokers; for the two, the three groups did not differ. For five of the cytokines (IL1β, IL2, IL6, IL8, IFNγ), the differences reached statistical significance, with overall significant P values reaching a threshold for FDR < 0.1 (Table 2). There were significant differences (P values reaching a threshold for FDR q < 0.1) between e-cig users and never-smokers for IL1β, IL6, and IFNγ and between e-cig users and smokers for IL1β. There was considerable overlap in values for individuals in the groups (Supplementary Fig. S1). Time since last cigarette, cigarettes per day when previously smoking, and gender were not significantly correlated with cell counts or cytokines.

Differential gene expression and methylation in bronchial epithelial cells

There were 2,452 differentially expressed transcripts (DET), corresponding to 2,093 unique genes across the groups (Supplementary Table S2). Unsupervised PCA and hierarchical clustering are shown in Fig. 1. The first principal component accounted for 31.7% of overall variation in gene expression. The expression profiles of never-smokers were closely clustered and separated from smokers, whereas the e-cig users and never-smokers were more similar to each other. E-cig users’ gene expressions were intermediate between smokers and never-smokers for 93% of the 2,452 DETs (33% expected, \( P \chi^2 < 0.0001 \); Fig. 1C, Supplementary Table S1). There were 181 transcripts that were related specifically to e-cig use (higher or lower than both smokers and never-smokers); the top 10 transcripts were MUC5B (4 transcripts), MICSAC, ZNF445, REEPI, ABHK4, LINC00589, and TMPRSS3 (Supplementary Table S2).

A subset of subjects (10 never-smokers, 12 e-cig users, and 10 smokers) were assessed for differential DNA methylation (DGM). There were 451 differentially methylated CpGs at FDR q < 0.1, corresponding to 273 unique genes and including 144 intergenic methylation loci (Supplementary Table S3). PCA and hierarchical clustering are shown in Fig. 1B. The first principal component accounted for 59.6% of the overall variation in methylation. There was clustering by group with e-cig users falling between the smokers and never-smokers. Of the 451 differentially methylated CpGs, for 97%, the e-cig users were intermediate between smokers and never-smokers (33% expected, P \( \chi^2 < 0.0001 \); Fig. 1C). There were 14 CpGs relating specifically to e-cig use (higher or lower than smokers and never-smokers; lower levels: RBBDL2, TTC16, ZNF815, and 3 intergenic CpGs; higher levels for AMZ1, KRT12, NOX5/MIR548H colocalized, NRF1, and 4 intergenic CpGs).

There were no patterns on PCA and heatmap by THC status for all three groups combined, and for smokers alone, indicating that the DETS and DGM were shown to be independent of THC status (Fig. 1).

In IPA, the top 20 common canonical pathways for DGM, xenobiotic metabolism signaling, NRF2-mediated oxidative stress response, aryl hydrocarbon receptor signaling, PXR/RXR activation, and LPS/IL1-mediated inhibition of RXR function (Fig. 2). Of the top 20 common canonical pathways for DGM, xenobiotic metabolism signaling and colorectal cancer metastasis signaling were the most common pathways, followed by HOTAIR Regulatory Pathway and Axonal Guidance Signaling.

Correlation of differential gene methylation expression

Among the 111 DGM CpG and DETs, within \pm 1.5 kb, that were statistically significant in both assays and present on both platforms, 102 (92%) were significantly correlated at FDR q < 0.1, corresponding to 56 unique genes; 94 were negative correlations (downregulation) and 8 were positive (upregulation; Fig. 3, Supplementary Table S4). Negatively correlated CpGs were more frequently enriched in
Table 2. Inflammatory cell counts and cytokines in BAL fluids of never-smokers, e-cig users, and smokers.

<table>
<thead>
<tr>
<th></th>
<th>Never-smoker (n = 40)</th>
<th>E-cig user (n = 13)</th>
<th>Smoker (n = 16)</th>
<th>P value</th>
<th>Never vs. e-cig</th>
<th>Never vs. smokers</th>
<th>E-cig vs. smokers</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BAL cells</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Instilled saline (mL)</td>
<td>100 (100–140)</td>
<td>100 (100–140)</td>
<td>100 (100–140)</td>
<td>0.6</td>
<td>0.66</td>
<td>0.45</td>
<td>0.35</td>
</tr>
<tr>
<td>Recovery (mL)</td>
<td>57 (40–71)</td>
<td>55 (28–65)</td>
<td>46 (31–71)</td>
<td>0.002</td>
<td>0.27</td>
<td>0.004</td>
<td>0.2</td>
</tr>
<tr>
<td>Total cell yield (×10^6)</td>
<td>13 (8–34)</td>
<td>15 (5–28)</td>
<td>23 (11–64)</td>
<td>0.01</td>
<td>0.38</td>
<td>0.004</td>
<td>0.11</td>
</tr>
<tr>
<td><strong>Cell concentration (×10^5/L)</strong></td>
<td>238 (129–763)</td>
<td>306 (128–818)</td>
<td>434 (204–1,689)</td>
<td>0.001</td>
<td>0.22</td>
<td>0.0003</td>
<td>0.05</td>
</tr>
<tr>
<td>Macrophages (×10^5/L)</td>
<td>201 (97–649)</td>
<td>265 (111–760)</td>
<td>411 (161–1,588)</td>
<td>0.0002</td>
<td>0.13</td>
<td>&lt;0.0001</td>
<td>0.02</td>
</tr>
<tr>
<td>(%)</td>
<td>89 (61–100)</td>
<td>89 (69–100)</td>
<td>95 (79–100)</td>
<td>0.08</td>
<td>0.62</td>
<td>0.03</td>
<td>0.14</td>
</tr>
<tr>
<td>Lymphocytes (×10^5/L)</td>
<td>22 (0–159)</td>
<td>13 (0–70)</td>
<td>10 (0–59)</td>
<td>0.07</td>
<td>0.54</td>
<td>0.02</td>
<td>0.16</td>
</tr>
<tr>
<td>(%)</td>
<td>9 (0–37)</td>
<td>4 (0–27)</td>
<td>1 (0–19)</td>
<td>0.003</td>
<td>0.33</td>
<td>0.0009</td>
<td>0.03</td>
</tr>
<tr>
<td>Neutrophils (×10^6/L)</td>
<td>3 (0–31)</td>
<td>3 (0–30)</td>
<td>10 (0–118)</td>
<td>0.03</td>
<td>0.18</td>
<td>0.01</td>
<td>0.43</td>
</tr>
<tr>
<td>(%)</td>
<td>1 (0–9)</td>
<td>2 (0–8)</td>
<td>3 (0–9)</td>
<td>0.16</td>
<td>0.19</td>
<td>0.09</td>
<td>0.73</td>
</tr>
<tr>
<td>Eosinophils (×10^6/L)</td>
<td>0 (0–8)</td>
<td>0 (0–17)</td>
<td>0 (0–13)</td>
<td>0.53</td>
<td>0.4</td>
<td>0.35</td>
<td>1</td>
</tr>
<tr>
<td>(%)</td>
<td>0 (0–2)</td>
<td>0 (0–3)</td>
<td>0 (0–1)</td>
<td>0.64</td>
<td>0.41</td>
<td>0.52</td>
<td>0.79</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Cytokines (pg/mL)</th>
<th>Never-smoker (n = 42)</th>
<th>E-cig user (n = 15)</th>
<th>Smoker (n = 16)</th>
<th>P value</th>
<th>Never vs. e-cig</th>
<th>Never vs. smokers</th>
<th>E-cig vs. smokers</th>
</tr>
</thead>
<tbody>
<tr>
<td>IL1ß</td>
<td>0.82 (0.39)</td>
<td>1.51 (1.48)</td>
<td>6.08 (5.37)</td>
<td>&lt;0.0001</td>
<td>0.005</td>
<td>&lt;0.0001</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>IL2</td>
<td>0.38 (0.12)</td>
<td>0.35 (0.09)</td>
<td>0.31 (0.15)</td>
<td>0.01</td>
<td>0.38</td>
<td>0.005</td>
<td>0.10</td>
</tr>
<tr>
<td>IL4</td>
<td>0.04 (0.009)</td>
<td>0.04 (0.008)</td>
<td>0.04 (0.01)</td>
<td>0.56</td>
<td>0.28</td>
<td>0.62</td>
<td>0.66</td>
</tr>
<tr>
<td>IL6</td>
<td>0.99 (0.56)</td>
<td>1.56 (1.02)</td>
<td>4.21 (4.93)</td>
<td>&lt;0.0001</td>
<td>0.02</td>
<td>&lt;0.0001</td>
<td>0.07</td>
</tr>
<tr>
<td>IL8</td>
<td>28.37 (37.2)</td>
<td>66.09 (115.71)</td>
<td>88.52 (114.52)</td>
<td>0.008</td>
<td>0.30</td>
<td>0.001</td>
<td>0.30</td>
</tr>
<tr>
<td>IL10</td>
<td>0.09 (0.02)</td>
<td>0.09 (0.02)</td>
<td>0.09 (0.029)</td>
<td>0.27</td>
<td>0.42</td>
<td>0.13</td>
<td>0.53</td>
</tr>
<tr>
<td>IL15</td>
<td>1.80 (1.78)</td>
<td>1.59 (0.96)</td>
<td>1.36 (0.42)</td>
<td>0.74</td>
<td>0.78</td>
<td>0.45</td>
<td>0.65</td>
</tr>
<tr>
<td>IL12p70</td>
<td>0.14 (0.04)</td>
<td>0.13 (0.03)</td>
<td>0.12 (0.04)</td>
<td>0.11</td>
<td>0.20</td>
<td>0.05</td>
<td>0.59</td>
</tr>
<tr>
<td>IFNγ</td>
<td>0.91 (0.27)</td>
<td>0.74 (0.31)</td>
<td>0.65 (0.33)</td>
<td>0.005</td>
<td>0.02</td>
<td>0.0008</td>
<td>0.54</td>
</tr>
<tr>
<td>TNFα</td>
<td>0.45 (0.17)</td>
<td>0.49 (0.20)</td>
<td>0.52 (0.23)</td>
<td>0.44</td>
<td>0.49</td>
<td>0.22</td>
<td>0.68</td>
</tr>
</tbody>
</table>

Note: Significant P values at the 0.05 level are bolded. Significant P values after correction for multiple testing by adjusted FDR at the 0.1 level are indicated by asterisks. BAL with red blood cell contamination (2 never-smokers and 2 e-cig users) were removed for inflammatory cell counts which altered total cell counts. Median, range, and SD are presented as raw values.

promoters, whereas positively correlated CpGs were more frequently found in nonpromoter enhancers (Fig. 3). IPA analysis of the 56 unique genes showed the greatest enrichment for beta-naphthoflavone (Fig. 4A). The mechanistic networks for beta-naphthoflavone that are related to smoking included the aryl hydrocarbon receptor (AHR), the aryl hydrocarbon receptor nuclear translocator (ARNT), and nuclear factor (erythroid-derived 2)-like 2 (NFE2L2; Fig. 4A). The DET genes regulated by beta-naphthoflavone included 12 genes (ABCC3, AHRR, AHRB10, AKR1C1, ALDH3A1, CYP1B1, GPX2, NQO1, SLCA11, TIMP3, TNFRSF19, and UGT1A1; Fig. 4A and B), where all except one (TNFRSF19) were hypomethylated, with highest expression in smokers, lowest in never-smokers, and e-cig users intermediate. The most represented disease was cancer, encompassing 51 genes (91%, 51/56), which included 27 (53%, 27/51) involved in respiratory tumors (Supplementary Table S4).

Discussion

This study is the first to investigate inflammatory biomarkers, gene methylation, and gene expression among smokers, e-cig users, and never-smokers in lung samples, building upon the knowledge of known differences between smokers and never-smokers (9, 28, 29). E-cigs have the potential to foster smoking cessation (2) and substantially reduce exposure to combustible tobacco toxicants, but the relative effect on the lung is unclear (1, 9). In this cross-sectional study, using two methods of lung sampling (BAL for inflammatory cells and cytokines, and lung epithelial cell brushings for gene expression and methylation), we found that almost all of the biomarkers in the e-cig users were intermediate between current and never-smokers, occurring substantially more than by chance alone. These cross-sectional findings suggest that smoking effects on the lung may be at least partially reversible in smokers switching to e-cigs, findings which need to be substantiated in longitudinal studies including randomized trials. There may be some effects specific to e-cigs; we found expression for some genes and DNA methylation of some loci where values for e-cig users were higher or lower than both never-smokers’ and non-smokers’ (e.g., MUC5B and other important lung proteins). The canonical pathways that differed most among the three groups are well-known to be affected by smoking, including xenobiotic metabolism signaling, NRF2-mediated oxidative stress response, AHR signaling, PXR/RXR activation, and LPS/IL1-mediated inhibition of RXR function (30–32). Importantly, the DGM were correlated with...
DET, corroborating biological impact of the DGM, especially in smoking-related pathways.

Inflammation is considered to play an important role in lung carcinogenesis and COPD; it is known that inflammatory biomarkers are higher among smokers than never-smokers. (29, 33–35) The e-cig users in this study had higher inflammatory infiltrates than never-smokers, and lower than for smokers. Compared with never-smokers, there were significant differences for e-cig users for IL1β, IL6, and IFNγ, associated with lung cancer (33–35); also for IL2, IL6, IL6, and IFNγ, associated with COPD (36, 37). E-cig users were significantly different from smokers for IL1β.

There were distinct patterns for DNA methylation and gene expression distinguishing smokers, e-cig users, and never-smokers, where e-cig users’ levels also were intermediate between smokers and never-smokers (97% and 92%, respectively vs. 33% by chance alone). Among the top genes included those known to be affected by smoking such as those involved in AHR and ARNT signaling pathways, and CYPs and other xeno-metabolizing enzymes (i.e., ALDH3A1 and CYP1B1), increasing DNA damage in a dose-dependent manner and associated with lung tumorigenesis in experimental animals and humans (38–43).

In this study, compared with smokers, e-cig users had lower expression levels of AHR and xenobiotic metabolizing enzymes consistent with
Other important cancer and COPD pathways lower in expression in e-cig users compared with smokers included the \textit{NRF2} oxidative stress response pathway, involved in the protection of cells from oxidative stress from cigarette smoke \citep{44, 45}, and a regulator of innate immunity \citep{46}. Also found were effects on the \textit{PXR} and the \textit{RXR} pathways that affect xenobiotic metabolism through cytochrome P450s \citep{47}. The \textit{RXR} are nuclear receptors for retinoids that affect the regulation of growth and differentiation in normal and tumor cells, including lung cancer and precursors to lung cancer \citep{48}.

Staudt and colleagues measured gene expression in healthy smokers exposed to a nicotine-containing e-cig use for one day and conducted

The common canonical pathways between differentially methylated genes and differentially expressed genes from brushings of lung epithelial cells among never-smokers, e-cig users, and smokers. The top 20 common canonical pathways based on the score ($-\log(P \text{ value})$) by IPA with its annotation are shown with numbers of differentially methylated and expressed genes (next to bars). DE, differentially expressed; DM, differentially methylated.

The integration scheme between DNA methylation and gene expression from brushings of lung epithelial cells.

$^a$Adjusted for gender; $^b$Annotated transcripts with gene symbols; $^c$Including 273 probes associated with genes; $^d$32 paired sample analysis; $^e$Functional promoters (within 1,500 base pairs (bps) of a transcription start site (TSS); within 200 bps of a TSS (TSS200); 5’ untranslated regions (5’UTR); first exon (1stExon)).
serial bronchoscopies (one week before and on the day of use; ref. 17). They reported differential gene expression for 72 genes after the short-term e-cig exposure. Among these genes, 11 genes (15%) were also identified in our study with similar directions in changes of expression (ATAD2, HCAR3, IP6K3, LYPD3, MK67, MT1X, MT2A, PPP1R16B, RND3, SGK1, and ZBTB16). Separately, Gosh and colleagues conducted a proteomic analysis of smokers, e-cig users, and never-smokers, and reported changes in CYP1B1 and MUC5AC levels specific to e-cig users (16). Our data somewhat differed; these genes and MUC1I were intermediate for the e-cig users for gene expression, and also we found that MUC5B levels on gene expression were higher than both never-smokers and smokers. Further, their group revealed increased neutrophil elastase and matrix metalloprotease (MMP) levels as well as activities in e-cig users’ lung, resulting in disrupting the protease–antiprotease balance (18). Specifically, they observed higher protein levels for MMP2 and MMP9 among e-cig users compared with never-smokers. However, our study for transcription levels found no statistical differences for both genes, but MMP7 was shown to be intermediate between never-smokers and smokers.

There are some limitations that should be considered in the interpretation of these study results. Although this study focused on critically important measures of biological effects on inflammation, gene expression, and DNA methylation, there may be other biomarkers of exposure and effect which were not included. Additional studies are needed to explore these. This study also has small numbers, and although sufficiently powered to demonstrate the reported differences for this study, it may be that additional effects would be found with a larger study, e.g., gender differences. Further, because use of e-cigs is relatively recent, the study participants had used them for a relatively short period of time. These findings may not extrapolate to longer use; as use continues in the population, it will be important to examine a population with longer exposure. In an observational study such as this one, there was no control for the type of e-cig use. There may be differences based on the characteristics of the e-cig. In addition, the cross-sectional design precludes any temporal assessments of biomarker changes, and it is not possible to ascertain causality. Further, study participants were volunteers whose characteristics may not be generalizable to the general population of smokers and e-cig users, especially those older than 21 to 30 years. Another limitation is that the study results may be affected by unknown confounders, perhaps relating to characteristics of the study participants use of cigarettes (e.g., depth in inhalation, brand of cigarette) or of e-cigs (e.g., characteristics related to the choice to use e-cigs as well as frequency and duration of use). A further limitation of the study is that we did not include former smokers who did not use e-cigs. Thus, we do not know if the observed differences between smokers and e-cig users reflect smoking cessation by any means or changes specific to the e-cigs. Finally, we were limited by the study size; a larger study would allow for greater stability of estimates.

This study has important strengths. It is the first to describe inflammatory cells, cytokines, gene methylation, and with gene expression in current e-cig users, directly examining the lung as the target organ. We studied subjects with a narrow age range (21–30) to avoid age-related effects on lung physiology, and in order to represent typical e-cig users. Further, we investigated multiple biomarkers of effect to understand use at the biological and mechanistic level, providing a comprehensive description of e-cig use, and demonstrating consistency among a large group of biomarkers sampled in different ways from the lung.

There has been a recent and significant epidemic for vapers of cannabinoid oils and nicotine-containing e-cig users suffering acute lung injury and deaths (https://www.cdc.gov/tobacco/basic_information/...).
tion/e-cigarettes/severe-lung-disease.html). The reported illnesses and pathology differed, where some investigators believe that the etiology is related to altered lipid homeostasis (7, 49) or analogies to smoking-related damage and chemical insult (5). If the acute lung injury is occurring in nicotine e-cig users (there may be false denials of vaping oils or mis-diagnosis), then our data indicate that the latter hypothesis for smoking-related damage is not correct. However, we have not measured markers of lipid homeostasis and other markers of lung integrity such as surfactant, which needs further study.

In summary, we compared lung inflammation, DNA methylation, and gene expression for never-smokers, smokers, and e-cig users using bronchoscopy. The results were very consistent among the various biomarker methods and different lung sampling techniques. E-cig users were found to be intermediate between smokers and never-smokers for biomarkers of inflammation and for gene methylation and expression, including known smoking-related pathways. The e-cig levels were more closely related to never-smokers. Although these findings are cross-sectional and therefore cannot be extrapolated with regards to temporality or causality, our findings are consistent with the hypothesis that e-cigs may be less harmful than smoking, at least for the smoking-related biomarkers measured herein, and there may be some unique effects of e-cigs. The findings are also consistent with the hypothesis that e-cig use has harmful effects compared with never smoking. The results may also be affected by study subjects who modify their tank-based e-cigs. Further studies, including longitudinal studies and randomized trials, are needed that also include long-term, never-smoking e-cig users and former smokers who quit using methods other than e-cigs. Understanding the biological impact of e-cig use, particularly on a target organ such as the lung, is critically important because of the high prevalence of use of these devices.

Disclosure of Potential Conflicts of Interest

P.G. Shields has provided expert testimony for law firms representing plaintiffs in tobacco litigation. No potential conflicts of interest were disclosed by the other authors.

References


Authors’ Contributions

Conception and design: M.-A. Song, J.L. Freudenheim, M.D. Wewers, P.G. Shields
Development of methodology: S.A. Reisinger, M.D. Wewers, P.G. Shields
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): Q.A. Nickerson, S.A. Reisinger, M.D. Wewers
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): M.-A. Song, J.L. Freudenheim, T.M. Brasky, J.P. McLay, S.A. Reisinger, D.J. Smiraglia, P.G. Shields
Writing, review, and/or revision of the manuscript: M.-A. Song, J.L. Freudenheim, T.M. Brasky, E.A. Mathe, J.P. McLay, S.A. Reisinger, D.J. Smiraglia, M.D. Wewers, P.G. Shields
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): M.-A. Song, Q.A. Nickerson, S.A. Reisinger, D.Y. Weng, K.L. Ying, P.G. Shields
Study supervision: S.A. Reisinger, P.G. Shields

Acknowledgments

Research reported in this publication was supported by funding from the NCI of the NIH (P30 CA016058), the FDA Center for Tobacco Products (CTP, P50CA189088 and R21HL14401), the National Center for Advancing Translational Sciences (UL1TR001070), Pelotonia Intramural Research Funds, and the Prevent Cancer Foundation. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or the FDA. The authors thank the Genomics Shared Resource for performing the GeneChip Human Transcriptome Array 2.0, Center for Clinical and Translational Science for measuring the inflammatory cytokines, and Department of Pathology for BAL differential cell counts at The Ohio State University (OSU, Columbus, OH). The authors also thank the Genomics Shared Resource at Roswell Park Cancer Institute (Buffalo, NY) for conducting the Illumina Infinium MethylationEPIC BeadChip. The authors acknowledge the support of the Bioinformatics Shared Resource and the Biostatistics Shared Resource at OSU. The authors also thank the study participants, the staff and nurses of the OSU Clinical Research Center, and Sahar Kamel for assisting in recruiting participants.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received October 8, 2019; revised November 14, 2019; accepted December 2, 2019; published first December 17, 2019.

Published OnlineFirst December 17, 2019; DOI: 10.1158/1055-9965.EPI-19-1245

Downloaded from cebp.aacrjournals.org on September 14, 2021. © 2020 American Association for Cancer Research.